KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nasdaq (NDAQ) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Nasdaq (NDAQ) over the last 17 years, with Q4 2025 value amounting to $604.0 million.

  • Nasdaq's Cash & Equivalents rose 202.7% to $604.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $604.0 million, marking a year-over-year increase of 202.7%. This contributed to the annual value of $604.0 million for FY2025, which is 202.7% up from last year.
  • Nasdaq's Cash & Equivalents amounted to $604.0 million in Q4 2025, which was up 202.7% from $470.0 million recorded in Q3 2025.
  • Nasdaq's Cash & Equivalents' 5-year high stood at $5.3 billion during Q2 2023, with a 5-year trough of $266.0 million in Q3 2024.
  • Its 5-year average for Cash & Equivalents is $963.7 million, with a median of $462.0 million in 2022.
  • Per our database at Business Quant, Nasdaq's Cash & Equivalents soared by 167408.64% in 2023 and then plummeted by 9501.87% in 2024.
  • Over the past 5 years, Nasdaq's Cash & Equivalents (Quarter) stood at $393.0 million in 2021, then rose by 27.74% to $502.0 million in 2022, then dropped by 9.76% to $453.0 million in 2023, then surged by 30.68% to $592.0 million in 2024, then rose by 2.03% to $604.0 million in 2025.
  • Its Cash & Equivalents stands at $604.0 million for Q4 2025, versus $470.0 million for Q3 2025 and $732.0 million for Q2 2025.